Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
Archives of Neurology, 63 (11), 1545-1550
But the drug hit a supply shortage in late 2021 due to manufacturing issues, which the manufacturer managed to fix in the second half of 2022
Currently, three AAV-mediated PKP2-related ARVC gene therapies have received FDA approval to enter phase I clinical trials: 301 TN-401 (NCT06228924), LX2020 (NCT06109181), and RP-A601 (NCT05885412)
For women with normal cycles, effects are unclear but likely minimal
Prescribed through a Healthspan Membership with clinician-led evaluation and ongoing care to manage dosing, labs, and long-term health
US$ 29.23
US$ 26.72
US$ 20.86
US$ 28.68
US$ 22.71
US$ 25.57
